Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruiguang Zhang

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Cancer Pathogenesis and Therapy|November 3, 2025
Radiotherapy combined with first-line anti-programmed cell death protein 1 (PD-1) immunotherapy and chemotherapy for patients with advanced non-small cell lung cancer: A bicentric retrospective studyYu Huang, Peng Ding, Ruiguang Zhang, et al.
BMC Medicine|September 13, 2021
Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective studyYongchang Zhang, Xiangyu Zhang, Ruiguang Zhang, et al.
Microbiology Spectrum|November 17, 2021
Alterations of the Human Lung and Gut Microbiomes in Non-Small Cell Lung Carcinomas and Distant MetastasisHui Lu, Na L Gao, Fan Tong, et al.
Chinese Medical Journal|September 23, 2024
The role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective studyLingjuan Chen, Yi Kong, Fan Tong, et al.
Targeted Oncology|June 23, 2023
Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung CancerNan Zheng, Yimin Zhang, Yue Zeng, et al.
Journal of Hematology & Oncology|July 22, 2020
CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancerJian Wang, Ruiguang Zhang, Zhenyu Lin, et al.
Clinical and Translational Medicine|January 27, 2022
BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancerJian Wang, Yingzhuo Xu, Xinrui Rao, et al.
JCO Precision Oncology|March 23, 2023
Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With <i>ROS1</i>-Rearranged Advanced Lung Adenocarcinoma: A Multicenter, Retrospective Cohort StudyZhe Huang, Huan Yan, Liang Zeng, et al.
Iscience|October 1, 2024
Development of a prognostic nomogram for advanced non-small cell lung cancer using clinical characteristicsHaoyue Qin, Zhe Huang, Huan Yan, et al.
Iscience|August 20, 2025
Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLCLianxi Song, Liang Zeng, Qinqin Xu, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Cancer Pathogenesis and Therapy|November 3, 2025
Radiotherapy combined with first-line anti-programmed cell death protein 1 (PD-1) immunotherapy and chemotherapy for patients with advanced non-small cell lung cancer: A bicentric retrospective studyYu Huang, Peng Ding, Ruiguang Zhang, et al.
BMC Medicine|September 13, 2021
Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective studyYongchang Zhang, Xiangyu Zhang, Ruiguang Zhang, et al.
Microbiology Spectrum|November 17, 2021
Alterations of the Human Lung and Gut Microbiomes in Non-Small Cell Lung Carcinomas and Distant MetastasisHui Lu, Na L Gao, Fan Tong, et al.
Chinese Medical Journal|September 23, 2024
The role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective studyLingjuan Chen, Yi Kong, Fan Tong, et al.
Targeted Oncology|June 23, 2023
Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung CancerNan Zheng, Yimin Zhang, Yue Zeng, et al.
Journal of Hematology & Oncology|July 22, 2020
CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancerJian Wang, Ruiguang Zhang, Zhenyu Lin, et al.
Clinical and Translational Medicine|January 27, 2022
BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancerJian Wang, Yingzhuo Xu, Xinrui Rao, et al.
JCO Precision Oncology|March 23, 2023
Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With <i>ROS1</i>-Rearranged Advanced Lung Adenocarcinoma: A Multicenter, Retrospective Cohort StudyZhe Huang, Huan Yan, Liang Zeng, et al.
Iscience|October 1, 2024
Development of a prognostic nomogram for advanced non-small cell lung cancer using clinical characteristicsHaoyue Qin, Zhe Huang, Huan Yan, et al.
Iscience|August 20, 2025
Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLCLianxi Song, Liang Zeng, Qinqin Xu, et al.
Pageof 7